

2015 ASCO Annual Meeting UChicago Presentations

Date
Printed: Wednesday, May 27, 2015

Friday, May 29, 2015

Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract #	Poster Board #
1:00 PM	3:15 PM	S406	Extended Education Session	On the Shoulders of Giants: Chronic Lymphocytic Leukemia—Evolution of Targeted and Immunomodulatory Therapies	Soodalter	
4:30 PM	5:45 PM	E354b	Education Session	Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies	Renz	

Saturday, May 30, 2015

Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract #	Poster Board #
8:00 AM	11:30 AM	S Hall A	Poster Session	Breast Cancer—HER2/ER		
			<i>Maysa M. Abu-Khalaf, MD</i>	<i>A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer</i>	TPS628	115b
8:00 AM	11:30 AM	S Hall A	Poster Session	Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy		
			<i>Manish Sharma, MD</i>	<i>A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer</i>	1041	155
			<i>Peter H. O'Donnell, MD</i>	<i>Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity</i>	1049	163
			<i>Steven J. Chmura, MD, PhD</i>	<i>NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy in early-stage breast cancer</i>	TPS1105	216b
8:00 AM	11:30 AM	S Hall A	Poster Session	Developmental Therapeutics—Immunotherapy		
			<i>Narendiran Rajasekaran</i>	<i>Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in breast cancer</i>	3031	357
			<i>Jason John Luke, MD, FACP</i>	<i>Effect of denileukin diftitox (DD) on vaccine-induced T-cell responses and depletion of T-regulatory cells</i>	3046	372
1:15 PM	4:45 PM	S Hall A	Poster Session	Genitourinary (Prostate) Cancer		
			<i>Michael William Drazer, MD</i>	<i>National prostate cancer screening rates following the 2012 United States Preventive Services Task Force recommendation</i>	5026	18
			<i>Rahul Raj Aggarwal, MD</i>	<i>The role of highly selective androgen receptor (AR) targeted therapy in men with biochemical relapse after prostatectomy</i>	TPS5084	70b
1:15 PM	4:45 PM	S Hall A	Poster Session	Gynecologic Cancer		
			<i>Satoshi Takeuchi, M.D., Ph.D.</i>	<i>Phase 2 studies of multiple peptides cocktail vaccine for treatment-resistant cervical and endometrial cancer</i>	5567	125
			<i>Emily Meichun Ko, MD, MSCR</i>	<i>Impact of older age on chemotherapy toxicity and quality of life in women with advanced-stage breast cancer</i>	5604	162
1:15 PM	4:45 PM	S Hall A	Poster Session	Head and Neck Cancer		
			<i>Tanguy Y. Seiwert, MD</i>	<i>Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody in head and neck cancer</i>	6017	340
			<i>Victoria Meucci Villafior, MD</i>	<i>Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy in head and neck cancer</i>	6050	373
			<i>Everett E. Vokes, MD</i>	<i>A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab monotherapy in head and neck cancer</i>	6060	384
			<i>Vassiliki Saloura, MD</i>	<i>Patterns of CD8+ T-cell infiltration and immune escape mechanisms in head and neck cancer</i>	6078	402
			<i>Zhixiang Zuo, PhD</i>	<i>Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype in head and neck cancer</i>	6079	403
			<i>Johannes Bragelmann, MD</i>	<i>Comparison of two large, genetically and clinically annotated head and neck cancer (HNC) cohorts</i>	6080	404
1:15 PM	4:45 PM	S Hall A	Poster Session	Patient and Survivor Care		
			<i>Tri Minh Le</i>	<i>Frailty and outcomes in older adults undergoing pancreaticoduodenectomy</i>	9530	189
			<i>Heather E. Wheeler, PhD</i>	<i>Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian T1 and T2 populations</i>	9570	229
			<i>Jonas A. De Souza, MD</i>	<i>Cost communication preferences, financial burden, and health-related quality-of-life (HRQL) in breast cancer patients</i>	9632	291
4:45 PM	6:00 PM	S100a	Special Session	Payment Reform in Oncology: The Way Forward	Polite	
8:00 AM	9:15 AM	S404	Education Session	Alternatives to ASP-Plus-Six: What Are the Options?	Polite	
1:15 PM	4:15 PM	S100bc	Oral Abstract Session	Cancer Prevention, Genetics, and Epidemiology	Ahsan	
1:15 PM	4:15 PM	E Arie Crown Theater	Oral Abstract Session	Leukemia, Myelodysplasia, and Transplantation		
1:45 PM	1:57 PM		<i>Wendy Stock, MD</i>	<i>New Biomarkers and Prognostic Indicators in Leukemia and Myelodysplastic Syndrome</i>		
3:29 PM	3:39 PM		<i>Evgeny Klyuchnikov, MD</i>	<i>Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant in acute myeloid leukemia</i>	7009	
3:49 PM	4:01 PM		<i>Michael Russell Bishop, MD, FACP</i>	<i>Cellular Therapies Including Hematopoietic Cell Transplantation and Chimeric Antigen Receptor Transgenic T Cells</i>		
3:00 PM	6:00 PM	E Hall D1	Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		
3:00 PM	3:12 PM		<i>Gerard Zalzman, MD, PhD</i>	<i>Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma</i>	7500	
5:00 PM	5:12 PM		<i>Suresh Senan, MRCP, FRCR, PhD</i>	<i>Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis), and docetaxel (Doc) versus Cis and Doc</i>	7506	
8:00 AM	11:30 AM	S Hall A	Poster Discussion Session	Breast Cancer—HER2/ER		

			<i>Kala Visvanathan, MD, MHS</i>	<i>DNA methylation in serum as an independent marker of outcome and treatment response</i>	518	6
			<i>George Somlo, MD</i>	<i>Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb)</i>	520	8
			<i>Laura van't Veer, PhD</i>	<i>DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients</i>	521	9
			<i>Debu Tripathy, MD</i>	<i>Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor</i>	524	12
8:00 AM	11:30 AM	S Hall A	Poster Discussion Session	Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics		
			<i>Glenwood D. Goss</i>	<i>ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth</i>	2510	226

Sunday, May 31, 2015

Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract #	Poster Board #
7:30 AM	9:15 AM	E Hall D1	Highlights of the Day Session	Highlights of the Day Session I Including Clinical Trial Participation Awards		
8:15 AM	8:30 AM		<i>Richard A. Larson</i>	<i>Leukemia, Myelodysplasia, and Transplantation</i>		
8:00 AM	11:30 AM	S Hall A	Poster Session	Leukemia, Myelodysplasia, and Transplantation		
			<i>Hagop M. Kantarjian, MD</i>	<i>Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R)</i>	7043	32
			<i>Gary J. Schiller, MD</i>	<i>Allogeneic hematopoietic cell transplant (HCT) in patients (pts) ≥ 60 years of age with fi</i>	7055	44
			<i>Hagop Kantarjian, MD</i>	<i>Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute</i>	7057	46
			<i>Lewis R. Silverman, MD</i>	<i>Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase II</i>	7092	81
			<i>Guillermo Garcia-Manero, MD</i>	<i>Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed</i>	TPS7103	87b
8:00 AM	11:30 AM	S Hall A	Poster Session	Lymphoma and Plasma Cell Disorders		
			<i>Andrzej J. Jakubowiak</i>	<i>A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without</i>	8573	391
			<i>Maria-Victoria Mateos, MD, PhD</i>	<i>A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus</i>	TPS8608	422b
8:00 AM	11:30 AM	S Hall A	Poster Session	Pediatric Oncology		
			<i>Mark A. Applebaum, MD</i>	<i>Second malignancies in neuroblastoma patients: A report from the International Neurobl</i>	10019	89
8:00 AM	11:30 AM	S Hall A	Poster Session	Tumor Biology		
			<i>Zahi Ibrahim Mitri, MD</i>	<i>TBCRC-010: Phase I/II study of dasatinib in combination with zoledronic acid (ZA) for th</i>	11080	294
			<i>Atsushi Takano, MD, PhD</i>	<i>Characterization of LASEP3 as a serological and prognostic biomarker and a therapeutic</i>	11088	302
8:00 AM	9:30 AM	S102	Clinical Science Symposium	Predicting and Improving Adverse Outcomes in Older Patients with Cancer		
9:00 AM	9:12 AM		<i>William Dale, MD, PhD</i>	<i>Prediction of Death in Older Patients: Close to the End?</i>		
9:45 AM	11:00 AM	S504	Education Session	Let the Sunshine In: Industry's Impact on Oncology Research and Practice	Ratain	
8:00 AM	9:30 AM	E450	Clinical Science Symposium	Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data		
8:00 AM	8:12 AM		<i>David A. Reardon, MD</i>	<i>ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) pl</i>	2009	
9:45 AM	11:00 AM	S100bc	Education Session	Best of the Rest: Top Head and Neck Abstracts from 2014-2015 Oncology Meetings	Seiwert	
8:00 AM	11:00 AM	E Hall D2	Oral Abstract Session	Gastrointestinal (Noncolorectal) Cancer		
8:00 AM	8:12 AM		<i>David Cunningham</i>	<i>Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotum</i>	4000	
8:12 AM	8:24 AM		<i>Yung-Jue Bang, MD, PhD</i>	<i>Relationship between PD-L1 expression and clinical outcomes in patients with advanced</i>	4001	
10:24 AM	10:36 AM		<i>Matthew H. G. Katz, MD</i>	<i>Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) f</i>	4008	
4:30 PM	6:00 PM	E Hall D2	Clinical Science Symposium	To Lump or To Split: Molecular, Anatomic, and Etiologic Subtyping of Noncolorectal Gastr		
4:30 PM	4:42 PM		<i>Jeffrey S. Ross, MD</i>	<i>Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differ</i>	4009	
4:30 PM	6:00 PM	E Hall D1	Clinical Science Symposium	Immunotherapy in Lung Cancer: A Paradigm Shift		
4:30 PM	4:42 PM		<i>David R. Spigel, MD</i>	<i>A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-</i>	8009	
9:45 AM	12:45 PM	E Arie Crown Theater	Oral Abstract Session	Genitourinary (Prostate) Cancer		
9:45 AM	9:57 AM		<i>Howard I. Scher, MD</i>	<i>The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resista</i>	5000	
8:00 AM	11:30 AM	S Hall A	Poster Discussion Session	Leukemia, Myelodysplasia, and Transplantation		
			<i>Anthony Mato, MD</i>	<i>Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL reg</i>	7013	3
8:00 AM	11:30 AM	S Hall A	Poster Discussion Session	Pediatric Oncology		
			<i>Kirsten K. Ness, PT, PhD</i>	<i>Temporal trends in health status among adults in the Childhood Cancer Survivor Study (</i>	10020	90
8:00 AM	11:30 AM	S Hall A	Poster Discussion Session	Lymphoma and Plasma Cell Disorders		
			<i>Meletios A. Dimopoulos, MD</i>	<i>Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexa</i>	8525	342
11:30 AM	12:45 PM	E354b	Poster Discussion Session	Leukemia, Myelodysplasia, and Transplantation		

Monday, June 01, 2015

Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract #	Poster Board #
7:30 AM	9:15 AM	E Hall D1	Highlights of the Day Session	Highlights of the Day Session II Including Partners in Progress Award		
8:20 AM	8:40 AM		Blase N. Polite, MD, MPP	Health Services Research and Quality of Care		
1:15 PM	2:30 PM	E451b	Meet the Professor Session	Adjuvant Therapy for Corpus-Confin ed Endometrial Cancer: Who Do We Treat?	Fleming	
8:00 AM	11:30 AM	S Hall A	Poster Session	Gastrointestinal (Colorectal) Cancer		
			Federico Innocenti, MD, PhD	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colo	3599	92
8:00 AM	11:30 AM	S Hall A	Poster Session	Gastrointestinal (Noncolorectal) Cancer		
			Daniel Virgil Thomas Catenacci, MD	MET as a prognostic biomarker of survival in a large cohort of patients with gastroesoph	4034	143
			Hedy Lee Kindler, MD	POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancre	TPS4149	252b
1:15 PM	4:45 PM	S Hall A	Poster Session	Genitourinary (Nonprostate) Cancer		
			Tanya B. Dorff, MD	Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer	4542	215
1:15 PM	4:45 PM	S Hall A	Poster Session	Health Services Research and Quality of Care		
			Blase N. Polite, MD, MPP	Religious beliefs and stage at diagnosis in a biracial sample of newly diagnosed colon ca	6556	113
			Wesley Yin, PhD	Breast cancer progression and workplace productivity.	6586	143
			Fabrice Smielauskas, PhD	Trends in the costs and utilization of targeted cancer therapies for the privately insured	6597	154
			Jonas A. De Souza, MD	Grading financial toxicity based upon its impact on health-related quality of life (HRQoL).	6618	175
8:00 AM	11:30 AM	S Hall A	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		
			Steven Brad Maron, MD	ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II t	7511	258
			Mary E.R. O'Brien, MD, FRCP	Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of a	7540	287
			Karl R. Aigner, Prof. Dr. med.	Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for progressive and pre-treated	7556	304
			Alessandra Bulotta, MD	Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously tre	7558	306
			Lee M. Krug, MD	Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in p	7559	307
			Serena J Chee, BM, MRCP	The association of T cells with survival in mesothelioma.	7560	308
			Diego Luigi Cortinovis, MD	Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleur	7561	309
			Francesco Grossi, MD	MicroRNA prognostic signature in malignant pleural mesothelioma.	7562	310
			Constantine Alifrangis, MBBS, BSc, MRCP	High throughput therapeutic screening of malignant pleural mesothelioma (MPM) to ider	7563	311
			Andrea Cercek, MD	Confirmation of high prevalence of BAP1 inactivation in mesothelioma.	7564	312
			Raffit Hassan, MD	Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care cher	7565	313
			Arun Khattri, PhD	Immune escape correlates with an inflamed phenotype in malignant mesothelioma.	7566	314
			Evali Salgia, MD, PhD	Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictiv	7567	315
			David E. Gerber, MD	ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted	TPS7583	331a
			Mark Doherty, MB BCH BAO, MRCPi	Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin	TPS7586	332b
8:00 AM	11:30 AM	S Hall A	Poster Session	Lung Cancer—Non-Small Cell Metastatic		
			D. Ross Camidge, MD, PhD	Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ no	8062	385
1:15 PM	4:45 PM	S Hall A	Poster Session	Melanoma/Skin Cancers		
			Stefani Spranger, PhD	Effect of melanoma intrinsic β -catenin signaling on immune exclusion and resistance to i	9014	257
			Anna C. Pavlick, DO	Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobim	9020	263
			Antoni Ribas, MD, PhD	A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab	TPS9081	323a
			Jason John Luke, MD, FACP	Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide	TPS9087	326a
1:15 PM	2:30 PM	S504	Education Session	Shared Learning to Improve Cancer Outcomes in Adolescents and Young Adults: Pediatri		
3:00 PM	6:00 PM	E450	Oral Abstract Session	Tumor Biology		
5:00 PM	5:12 PM		Anthony W. Tolcher, MD	Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (Ds	11006	
5:12 PM	5:24 PM		Garrett Michael Frampton, PhD	Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alt	11007	
1:15 PM	4:15 PM	S100bc	Oral Abstract Session	Head and Neck Cancer		
1:51 PM	2:03 PM		Julie Ann Kish, MD	The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of rad	6003	
3:39 PM	3:51 PM		Tanguy Y. Seiwert, MD	Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamol	LBA6008	
1:15 PM	2:30 PM	E450	Education Session	Translating Knowledge into Therapeutic Progress in Myelodysplastic Syndromes	Odenike	
1:15 PM	4:15 PM	S406	Oral Abstract Session	Developmental Therapeutics—Immunotherapy		
1:39 PM	1:51 PM		Thomas Gajewski, MD, PhD	Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor	3002	

9:45 AM	12:45 PM	E Arie Crown Theater	Oral Abstract Session	Genitourinary (Nonprostate) Cancer		
9:45 AM	9:57 AM		<i>Toni K. Choueiri, MD</i>	<i>Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Ass</i>	4500	
10:09 AM	10:21 AM		<i>Elizabeth R. Plimack, MD, MS</i>	<i>Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarkers</i>	4502	
8:00 AM	11:00 AM	N Hall B1	Oral Abstract Session	Breast Cancer—HER2/ER		
8:12 AM	8:24 AM		<i>Maura N. Dickler, MD</i>	<i>Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine</i>	501	
3:00 PM	6:00 PM	N Hall B1	Oral Abstract Session	Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy		
4:00 PM	4:12 PM		<i>Tiffany A. Traina, MD</i>	<i>Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor</i>	1003	
1:15 PM	4:45 PM	S Hall A	Poster Discussion Session	Cancer Prevention, Genetics, and Epidemiology		
			<i>John M. Kacmar, MD</i>	<i>Sarcoma: A Lynch syndrome (LS)-associated malignancy?</i>	1516	339
4:45 PM	6:00 PM	E Arie Crown Theater	Poster Discussion Session	Genitourinary (Nonprostate) Cancer		

Tuesday, June 02, 2015

Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract #	Poster Board #
9:45 AM	12:45 PM	E354b	Oral Abstract Session	Myeloma		
10:33 AM	10:45 AM		<i>Todd M. Zimmerman, MD</i>	<i>Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and</i>	8510	
9:45 AM	11:15 AM	S406	Clinical Science Symposium	Molecular Drivers and Genomic Biomarkers in Genitourinary Cancers		
9:57 AM	10:09 AM		<i>Walter Michael Stadler, MD</i>	<i>Molecular Predictors of Response in Renal Cell Cancer</i>		
10:33 AM	10:45 AM		<i>Randy F. Sweis, MD</i>	<i>Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder</i>	4511	